An oral androgen receptor PROTAC degrader for prostate cancer.

被引：9
|
作者：
Neklesa, Taavi K.
Snyder, Lawrence B.
Bookbinder, Mark
Chen, Xin
Crew, Andrew P.
Crews, Craig M.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
273
引用
收藏
页数：1
相关论文
共 50 条
  • [1] An oral androgen receptor PROTAC degrader for prostate cancer.
    Neklesa, Taavi
    Snyder, Lawrence B.
    Willard, Ryan R.
    Vitale, Nicholas
    Raina, Kanak
    Pizzano, Jennifer
    Gordon, Deborah A.
    Bookbinder, Mark
    Macaluso, Jennifer
    Dong, Hanqing
    Liu, Zheng
    Ferraro, Caterina
    Wang, Gan
    Wang, Jing
    Crews, Craig M.
    Houston, John
    Crew, Andrew P.
    Taylor, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [2] An oral Androgen Receptor PROTAC degrader for prostate cancer
    Neklesa, Taavi K.
    Snyder, Lawrence B.
    Bookbinder, Mark
    Chen, Xin
    Crew, Andrew P.
    Crews, Craig M.
    Dong, Hanqing
    Gordon, Deborah
    Macaluso, Jennifer
    Raina, Kanak
    Rossi, AnnMarie
    Taylor, Ian
    Vitale, Nicholas
    Wang, Jing
    Willard, Ryan R.
    Zimmermann, Kurt
    [J]. CANCER RESEARCH, 2017, 77
  • [3] ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
    Neklesa, Taavi
    Snyder, Lawrence B.
    Willard, Ryan R.
    Vitale, Nicholas
    Pizzano, Jennifer
    Gordon, Deborah A.
    Bookbinder, Mark
    Macaluso, Jennifer
    Dong, Hanqing
    Ferraro, Caterina
    Wang, Gan
    Wang, Jing
    Crews, Craig M.
    Houston, John
    Crew, Andrew P.
    Taylor, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] ARV-330: Androgen receptor PROTAC degrader for prostate cancer.
    Neklesa, Taavi K.
    Jin, Meizhong
    Crew, Andrew P.
    Rossi, AnnMarie K.
    Willard, Ryan R.
    Dong, Hanqing
    Siu, Kam
    Wang, Jing
    Gordon, Deborah A.
    Chen, Xin
    Ferraro, Caterina
    Crews, Craig M.
    Coleman, Kevin
    Winkler, James D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [5] ARV-110: An androgen receptor PROTAC degrader for prostate cancer
    Neklesa, Taavi
    Snyder, Lawrence B.
    Willard, Ryan R.
    Vitale, Nicholas
    Raina, Kanak
    Pizzano, Jennifer
    Gordon, Deborah
    Bookbinder, Mark
    Macaluso, Jennifer
    Dong, Hanqing
    Liu, Zheng
    Ferraro, Caterina
    Wang, Gan
    Wang, Jing
    Crews, Craig M.
    Houston, John
    Crew, Andrew P.
    Taylor, Ian
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [6] An oral androgen receptor RIPTAC for prostate cancer.
    Raina, Kanak
    Eastman, Kyle J.
    Yu, Xinheng
    Forbes, Chris D.
    Jones, Kelli M.
    Mousseau, James J.
    Li, Hao
    Kayser-Bricker, Katherine J.
    Crews, Craig M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
    Chen, Linrong
    Han, Liuquan
    Mao, Shujun
    Xu, Ping
    Xu, Xinxin
    Zhao, Ruibo
    Wu, Zhihua
    Zhong, Kai
    Yu, Guangliang
    Wang, Xiaolei
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 216
  • [8] ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer
    Flanagan, J. J.
    Qian, Y.
    Gough, S. M.
    Andreoli, M.
    Bookbinder, M.
    Cadelina, G.
    Bradley, J.
    Rousseau, E.
    Willard, R.
    Pizzano, J.
    Crews, C. M.
    Crew, A. P.
    Taylor, I.
    Houston, J.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [9] Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
    Xiang, Weiguo
    Zhao, Lijie
    Han, Xin
    Qin, Chong
    Miao, Bukeyan
    McEachern, Donna
    Wang, Yu
    Metwally, Hoda
    Kirchhoff, Paul D.
    Wang, Lu
    Matvekas, Aleksas
    He, Miao
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (18) : 13487 - 13509
  • [10] Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer
    Shore, Neal D.
    Shen, John
    Devitt, Michael Edward
    Lu, Haolan
    Alicea, Jeanette
    Parameswaran, Janaki
    Chirnomas, Deborah
    Gao, Xin
    McKean, Meredith
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345